Akebia Therapeutics, Inc.

Zacks Investment Research•8/5/2026

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.

Akebia Therapeutics Q2 Earnings Call Highlights

GlobeNewsWire•8/5/2026

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

GlobeNewsWire•8/3/2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire•8/3/2026

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket trial to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G).

GlobeNewsWire•7/29/2026

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026, following the close of the financial markets.

GlobeNewsWire•7/2/2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3 newly-hired employees options to purchase an aggregate of 125,600 shares of Akebia's common stock on June 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire•6/30/2026

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO 2 VATE clinical trial program Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's largest privately held and fastest-growing kidney care provider, are pleased to announce today the decision by USRC Kidney Research to stop the Vafseo Outcomes In Center Experience (VOICE) trial following a planned interim analysis.

GlobeNewsWire•6/10/2026

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and it has been notified of eligibility to extend the expiration of a composition of matter patent covering Vafseo® (vadadustat).

Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near

Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference.

GlobeNewsWire•6/1/2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on May 29, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire•5/28/2026

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.